Psychobiotics Market Size, Trends, Growth, Report, Forecast 2028

Summary

Report Description

Global Psychobiotics market is projected to accomplish an extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.

A unique category of probiotics known as Psychobiotics helps people maintains their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although, there are not many products available in the market, the health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotics market in the future.

Increasing Demand for Probiotics to treat Anxiety and Depression

By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.

Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes and Actinobacteria were increased in subjects with major depressive disorders whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters including serotonin, dopamine, and GABA by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines—a pattern connected to the control of intestinal permeability—probiotics also assist in reducing systemic inflammation.

Given the fact of probiotics benefiting psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotics market in the upcoming years.

Surge in Cases of Anxiety and Depression

The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression is characterized by poor mood, loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common and depression was estimated to affect up to 4.4% of the world's population in 2015.

The COVID-19 pandemic also displayed its worst impacts on mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.

Rising Consumer Awareness

The market’s growth is also anticipated to be fueled by psychobiotic capacity to improve the body’s general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.

According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.

In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotics industry in the forecasted years.

Download Free Sample Report

Market Segmentation

Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agent, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.

Company Profiles

Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Attribute	Details
Base Year	2022
Historical Data	2018 – 2021
Estimated Year	2023
Forecast Period	2024 – 2028
Quantitative Units	Revenue in USD Million, Volume in Units and CAGR for 2018-2022 and 2023-2028F
Report coverage	Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends
Segments covered	· Psychotropic Agent · Form · Application
Regional scope	North America; Europe; Asia Pacific; South America; Middle East & Africa
Country scope	United States; Mexico; Canada; France; Germany; United Kingdom; Italy; Spain; Sweden; Poland; Slovakia; China; India; South Korea; Japan; Australia; Taiwan; Malaysia; Singapore; Brazil; Argentina; Colombia; South Africa; Saudi Arabia; UAE
Key companies profiled	InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, Lifted Naturals.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global psychobiotics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

Streptococcus
Bifidobacterium
Lactobacillus
Clostridium
Others

Psychobiotics Market, By Form:

Powder
Liquid/Fluid
Tablets
Others

Psychobiotics Market, By Application:

Stress Management
Mood Health & Mood Upliftment
Depression
Anxiety
Sleep Problems
Others

Psychobiotics Market, By Region:

North America

United States
Mexico
Canada

Europe

France
Germany
United Kingdom
Italy
Spain
Sweden
Poland
Slovakia

Asia-Pacific

China
India
South Korea
Japan
Australia
Taiwan
Malaysia
Singapore

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information:

Detailed analysis and profiling of additional market players (up to five)

Global Psychobiotics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validations

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

4.1. Brand Awareness

4.2. Preferred Mode of Purchase

4.3. Source of Information

4.4. Commonly Observed Mental Illness

4.5. Major Factors Contributing to Mental Illness

4.6. Willingness towards Psychobiotics Consumption

4.7. Commonly Observed Psychological Effect Post Consumption

4.8. Barriers to Adoption

5. Clinical Trial Analysis

5.1. Ongoing Clinical Trials

5.2. Completed Clinical Trials

5.3. Terminated Clinical Trials

5.4. Breakdown of Pipeline, By Development Phase

5.5. Breakdown of Pipeline, By Status

5.6. Breakdown of Pipeline, By Study Application

5.7. Breakdown of Pipeline, By Region

5.8. Clinical Trials Heat Map

6. Patent Analysis

7. Global Psychobiotics Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value & Volume

7.2. Market Share & Forecast

7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

7.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

7.2.5. By Region

7.2.6. By Company (2022)

7.3. Product Map

7.3.1. By Psychotropic Agent

7.3.2. By Form

7.3.3. By Application

7.3.4. By Distribution Channel

7.3.5. By Region

8. North America Psychobiotics Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value & Volume

8.2. Market Share & Forecast

8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

8.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

8.2.5. By Country

8.3. North America: Country Analysis

8.3.1. United States Psychobiotics Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value & Volume

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Psychotropic Agent

8.3.1.2.2. By Form

8.3.1.2.3. By Application

8.3.1.2.4. By Distribution Channel

8.3.2. Canada Psychobiotics Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value & Volume

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Psychotropic Agent

8.3.2.2.2. By Form

8.3.2.2.3. By Application

8.3.2.2.4. By Distribution Channel

8.3.3. Mexico Psychobiotics Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value & Volume

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Psychotropic Agent

8.3.3.2.2. By Form

8.3.3.2.3. By Application

8.3.3.2.4. By Distribution Channel

9. Europe Psychobiotics Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value & Volume

9.2. Market Share & Forecast

9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

9.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

9.2.5. By Country

9.3. Europe: Country Analysis

9.3.1. France Psychobiotics Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value & Volume

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Psychotropic Agent

9.3.1.2.2. By Form

9.3.1.2.3. By Application

9.3.1.2.4. By Distribution Channel

9.3.2. Germany Psychobiotics Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value & Volume

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Psychotropic Agent

9.3.2.2.2. By Form

9.3.2.2.3. By Application

9.3.2.2.4. By Distribution Channel

9.3.3. United Kingdom Psychobiotics Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value & Volume

9.3.3.2. Market Share & Forecasty

9.3.3.2.1. By Psychotropic Agent

9.3.3.2.2. By Form

9.3.3.2.3. By Application

9.3.3.2.4. By Distribution Channel

9.3.4. Italy Psychobiotics Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value & Volume

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Psychotropic Agent

9.3.4.2.2. By Form

9.3.4.2.3. By Application

9.3.4.2.4. By Distribution Channel

9.3.5. Spain Psychobiotics Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value & Volume

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Psychotropic Agent

9.3.5.2.2. By Form

9.3.5.2.3. By Application

9.3.5.2.4. By Distribution Channel

10. Asia-Pacific Psychobiotics Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value & Volume

10.2. Market Share & Forecast

10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

10.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

10.2.5. By Country

10.3. Asia-Pacific: Country Analysis

10.3.1. China Psychobiotics Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value & Volume

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Psychotropic Agent

10.3.1.2.2. By Form

10.3.1.2.3. By Application

10.3.1.2.4. By Distribution Channel

10.3.2. India Psychobiotics Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value & Volume

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Psychotropic Agent

10.3.2.2.2. By Form

10.3.2.2.3. By Application

10.3.2.2.4. By Distribution Channel

10.3.3. Japan Psychobiotics Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value & Volume

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Psychotropic Agent

10.3.3.2.2. By Form

10.3.3.2.3. By Application

10.3.3.2.4. By Distribution Channel

10.3.4. South Korea Psychobiotics Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value & Volume

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Psychotropic Agent

10.3.4.2.2. By Form

10.3.4.2.3. By Application

10.3.4.2.4. By Distribution Channel

10.3.5. Australia Psychobiotics Market Outlook

10.3.5.1. Market Size & Forecast

10.3.5.1.1. By Value & Volume

10.3.5.2. Market Share & Forecast

10.3.5.2.1. By Psychotropic Agent

10.3.5.2.2. By Form

10.3.5.2.3. By Application

10.3.5.2.4. By Distribution Channel

10.3.6. Taiwan Psychobiotics Market Outlook

10.3.6.1. Market Size & Forecast

10.3.6.1.1. By Value & Volume

10.3.6.2. Market Share & Forecast

10.3.6.2.1. By Psychotropic Agent

10.3.6.2.2. By Form

10.3.6.2.3. By Application

10.3.6.2.4. By Distribution Channel

10.3.7. Malaysia Psychobiotics Market Outlook

10.3.7.1. Market Size & Forecast

10.3.7.1.1. By Value & Volume

10.3.7.2. Market Share & Forecast

10.3.7.2.1. By Psychotropic Agent

10.3.7.2.2. By Form

10.3.7.2.3. By Application

10.3.7.2.4. By Distribution Channel

10.3.8. Singapore Psychobiotics Market Outlook

10.3.8.1. Market Size & Forecast

10.3.8.1.1. By Value & Volume

10.3.8.2. Market Share & Forecast

10.3.8.2.1. By Psychotropic Agent

10.3.8.2.2. By Form

10.3.8.2.3. By Application

10.3.8.2.4. By Distribution Channel

11. South America Psychobiotics Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value & Volume

11.2. Market Share & Forecast

11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

11.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

11.2.5. By Country

11.3. South America: Country Analysis

11.3.1. Brazil Psychobiotics Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value & Volume

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Psychotropic Agent

11.3.1.2.2. By Form

11.3.1.2.3. By Application

11.3.1.2.4. By Distribution Channel

11.3.2. Argentina Psychobiotics Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value & Volume

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Psychotropic Agent

11.3.2.2.2. By Form

11.3.2.2.3. By Application

11.3.2.2.4. By Distribution Channel

11.3.3. Colombia Psychobiotics Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value & Volume

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Psychotropic Agent

11.3.3.2.2. By Form

11.3.3.2.3. By Application

11.3.3.2.4. By Distribution Channel

12. Middle East and Africa Psychobiotics Market Outlook

12.1. Market Size & Forecast

12.1.1. By Value & Volume

12.2. Market Share & Forecast

12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)

12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)

12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)

12.2.4. By Distribution Channel (Supermarkets and Hypermarkets, Specialty Stores, Online, Others)

12.2.5. By Country

12.3. MEA: Country Analysis

12.3.1. South Africa Psychobiotics Market Outlook

12.3.1.1. Market Size & Forecast

12.3.1.1.1. By Value & Volume

12.3.1.2. Market Share & Forecast

12.3.1.2.1. By Psychotropic Agent

12.3.1.2.2. By Form

12.3.1.2.3. By Application

12.3.1.2.4. By Distribution Channel

12.3.2. Saudi Arabia Psychobiotics Market Outlook

12.3.2.1. Market Size & Forecast

12.3.2.1.1. By Value & Volume

12.3.2.2. Market Share & Forecast

12.3.2.2.1. By Psychotropic Agent

12.3.2.2.2. By Form

12.3.2.2.3. By Application

12.3.2.2.4. By Distribution Channel

12.3.3. UAE Psychobiotics Market Outlook

12.3.3.1. Market Size & Forecast

12.3.3.1.1. By Value & Volume

12.3.3.2. Market Share & Forecast

12.3.3.2.1. By Psychotropic Agent

12.3.3.2.2. By Form

12.3.3.2.3. By Application

12.3.3.2.4. By Distribution Channel

13. Market Dynamics

13.1. Drivers

13.2. Challenges

14. Market Trends & Developments

14.1. Recent Development

14.2. Mergers & Acquisitions

14.3. Product Launches

15. Pricing Analysis

16. Global Psychobiotics Market: SWOT Analysis

17. Porter’s Five Forces Analysis

17.1. Competition in the Industry

17.2. Potential of New Entrants

17.3. Power of Suppliers

17.4. Power of Customers

17.5. Threat of Substitute Types

18. Competitive Landscape

18.1. Business Overview

18.2. Type Offerings

18.3. Recent Developments

18.4. Key Personnel

18.5. SWOT Analysis

18.5.1. InnovixLabs

18.5.2. Bened Biomedical Co., Ltd

18.5.3. Nutrimmun GmbH

18.5.4. Kerry Group Plc.

18.5.5. Sabinsa Corporation

18.5.6. Lallemand Health Solutions Inc.

18.5.7. DuPont de Nemours, Inc.

18.5.8. Uplift Food Pty Ltd.

18.5.9. Nature's Bounty Co. Ltd.

18.5.10. BioGaia Group

18.5.11. The Life Extension Foundation

18.5.12. Lifted Naturals

19. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the best psychotropic agents used in production of Psychobiotics?

Some of the best known psychotropic agents used in the production of psychobiotics are Lactobacillus rhamnosus, Bifidobacterium longum, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus reuteri, Lactobacillus casei and Lactobacillus fermentum.

What are the major factors driving the growth of the Global Psychobiotics Market?

The growing prevalence of mental health issues such as anxiety, stress, and depression, rising awareness amongst worldwide population regarding their physical and mental health and for their overall bodily functions like consumer digestion, a surge in the number of patients with anxiety and depressive disorders are some of the principal market drivers for the global psychobiotics market.

Who are the key players operating in the Global Psychobiotics Market?

Some of the chief operating companies in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

What are the future trends that can augment the Global Psychobiotics Market?

Various collaborations between companies for the expansion of their product portfolio, increased number of research being held for better identification of new applications of psychobiotics, numerous studies on different bacterial strains that can act as psychobiotics and upcoming novel product innovations such as liquid or powder form of psychobiotics can grow the market lucratively.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Psychobiotics Market to Grow with an Impressive CAGR During the Forecast Period

Aug, 2021

Advancing healthcare industry is driving the growth in Global Psychobiotics Market in the forecast period, 2022-2026.

Buy Now